Arachidonic Acid Metabolites in Cardiovascular and Metabolic Diseases

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2018 Oct 27

PMID 30360467

Citations 164

Authors

Thomas Sonnweber

Alex Pizzini

Manfred Nairz

Gunter Weiss

Ivan Tancevski

Affiliations

Soon will be listed here.

Abstract

Lipid and immune pathways are crucial in the pathophysiology of metabolic and cardiovascular disease. Arachidonic acid (AA) and its derivatives link nutrient metabolism to immunity and inflammation, thus holding a key role in the emergence and progression of frequent diseases such as obesity, diabetes, non-alcoholic fatty liver disease, and cardiovascular disease. We herein present a synopsis of AA metabolism in human health, tissue homeostasis, and immunity, and explore the role of the AA metabolome in diverse pathophysiological conditions and diseases.

Citing Articles

Chemical Analysis and Antioxidant Activities of Resin Fractions from L. in Neuroblastoma SH-SY5Y Cells.

Georgantopoulos A, Kalousi F, Pollastro F, Tsialtas I, Kalogiouri N, Psarra A Molecules. 2025; 30(5).

PMID: 40076222 PMC: 11901618. DOI: 10.3390/molecules30050997.

Identification and verification of biomarkers associated with arachidonic acid metabolism in non-alcoholic fatty liver disease.

Li J, Su W, Wang Z, Ji X, Wang J, Wang K Sci Rep. 2025; 15(1):8521.

PMID: 40074804 PMC: 11903885. DOI: 10.1038/s41598-025-92972-z.

Investigation of Intestinal Health in Broiler Chickens Following Typhimurium and Coccidiosis Vaccination and Challenge with Typhimurium.

Pietruska A, Macklin K, Wang X, Krehling J, Dormitorio T, Hauck R J Poult Sci. 2025; 62:2025009.

PMID: 40060328 PMC: 11879612. DOI: 10.2141/jpsa.2025009.

GPCR drug discovery: new agents, targets and indications.

Lorente J, Sokolov A, Ferguson G, Schioth H, Hauser A, Gloriam D Nat Rev Drug Discov. 2025; .

PMID: 40033110 DOI: 10.1038/s41573-025-01139-y.

Blood pressure improvement after resection of non-functioning adrenal adenomas: influencing factors and serum metabolic features.

Zhang J, Wu P, Chen Y, Wang M, Song W Front Mol Biosci. 2025; 12:1524121.

PMID: 40017629 PMC: 11864923. DOI: 10.3389/fmolb.2025.1524121.

References

Izzo A, Deutsch D . Unique pathway for anandamide synthesis and liver regeneration. Proc Natl Acad Sci U S A. 2011; 108(16):6339-40. PMC: 3080979. DOI: 10.1073/pnas.1103566108. View

Smith W, Dewitt D, Garavito R . Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem. 2000; 69:145-82. DOI: 10.1146/annurev.biochem.69.1.145. View

Abrass C, Hori M . Alterations in Fc receptor function of macrophages from streptozotocin-induced diabetic rats. J Immunol. 1984; 133(3):1307-12. View

Witztum J, Steinberg D . Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest. 1991; 88(6):1785-92. PMC: 295745. DOI: 10.1172/JCI115499. View

Tsujimoto S, Kishina M, Koda M, Yamamoto Y, Tanaka K, Harada Y . Nimesulide, a cyclooxygenase-2 selective inhibitor, suppresses obesity-related non-alcoholic fatty liver disease and hepatic insulin resistance through the regulation of peroxisome proliferator-activated receptor γ. Int J Mol Med. 2016; 38(3):721-8. PMC: 4990319. DOI: 10.3892/ijmm.2016.2674. View

Chiang N, Fredman G, Backhed F, Oh S, Vickery T, Schmidt B . Infection regulates pro-resolving mediators that lower antibiotic requirements. Nature. 2012; 484(7395):524-8. PMC: 3340015. DOI: 10.1038/nature11042. View

Celotti F, Durand T . The metabolic effects of inhibitors of 5-lipoxygenase and of cyclooxygenase 1 and 2 are an advancement in the efficacy and safety of anti-inflammatory therapy. Prostaglandins Other Lipid Mediat. 2003; 71(3-4):147-62. DOI: 10.1016/s1098-8823(03)00039-x. View

Hodgson K, Morris J, Feterl M, Govan B, Ketheesan N . Altered macrophage function is associated with severe Burkholderia pseudomallei infection in a murine model of type 2 diabetes. Microbes Infect. 2011; 13(14-15):1177-84. DOI: 10.1016/j.micinf.2011.07.008. View

Mittal S, El-Serag H, Sada Y, Kanwal F, Duan Z, Temple S . Hepatocellular Carcinoma in the Absence of Cirrhosis in United States Veterans is Associated With Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol. 2015; 14(1):124-31.e1. PMC: 4690789. DOI: 10.1016/j.cgh.2015.07.019. View

10.

Falagas M, Kompoti M . Obesity and infection. Lancet Infect Dis. 2006; 6(7):438-46. DOI: 10.1016/S1473-3099(06)70523-0. View

11.

Paruchuri S, Jiang Y, Feng C, Francis S, Plutzky J, Boyce J . Leukotriene E4 activates peroxisome proliferator-activated receptor gamma and induces prostaglandin D2 generation by human mast cells. J Biol Chem. 2008; 283(24):16477-87. PMC: 2423236. DOI: 10.1074/jbc.M705822200. View

12.

Eguchi K, Manabe I, Oishi-Tanaka Y, Ohsugi M, Kono N, Ogata F . Saturated fatty acid and TLR signaling link β cell dysfunction and islet inflammation. Cell Metab. 2012; 15(4):518-33. DOI: 10.1016/j.cmet.2012.01.023. View

13.

Horrillo R, Gonzalez-Periz A, Martinez-Clemente M, Lopez-Parra M, Ferre N, Titos E . 5-lipoxygenase activating protein signals adipose tissue inflammation and lipid dysfunction in experimental obesity. J Immunol. 2010; 184(7):3978-87. DOI: 10.4049/jimmunol.0901355. View

14.

Brink C, Dahlen S, Drazen J, Evans J, Hay D, Nicosia S . International Union of Pharmacology XXXVII. Nomenclature for leukotriene and lipoxin receptors. Pharmacol Rev. 2003; 55(1):195-227. DOI: 10.1124/pr.55.1.8. View

15.

Duflot T, Roche C, Lamoureux F, Guerrot D, Bellien J . Design and discovery of soluble epoxide hydrolase inhibitors for the treatment of cardiovascular diseases. Expert Opin Drug Discov. 2014; 9(3):229-43. DOI: 10.1517/17460441.2014.881354. View

16.

Wang Y, Yan S, Xiao B, Zuo S, Zhang Q, Chen G . Prostaglandin F Facilitates Hepatic Glucose Production Through CaMKIIγ/p38/FOXO1 Signaling Pathway in Fasting and Obesity. Diabetes. 2018; 67(9):1748-1760. DOI: 10.2337/db17-1521. View

17.

Folco G, Rossoni G, Buccellati C, Berti F, Maclouf J, Sala A . Leukotrienes in cardiovascular diseases. Am J Respir Crit Care Med. 2000; 161(2 Pt 2):S112-6. DOI: 10.1164/ajrccm.161.supplement_1.ltta-22. View

18.

Martinez-Clemente M, Ferre N, Gonzalez-Periz A, Lopez-Parra M, Horrillo R, Titos E . 5-lipoxygenase deficiency reduces hepatic inflammation and tumor necrosis factor alpha-induced hepatocyte damage in hyperlipidemia-prone ApoE-null mice. Hepatology. 2010; 51(3):817-27. DOI: 10.1002/hep.23463. View

19.

Maekawa A, Kanaoka Y, Xing W, Austen K . Functional recognition of a distinct receptor preferential for leukotriene E4 in mice lacking the cysteinyl leukotriene 1 and 2 receptors. Proc Natl Acad Sci U S A. 2008; 105(43):16695-700. PMC: 2575482. DOI: 10.1073/pnas.0808993105. View

20.

Ingelsson E, Yin L, Back M . Nationwide cohort study of the leukotriene receptor antagonist montelukast and incident or recurrent cardiovascular disease. J Allergy Clin Immunol. 2012; 129(3):702-707.e2. DOI: 10.1016/j.jaci.2011.11.052. View